Talk:William Zoghbi
| This article must adhere to the biographies of living persons (BLP) policy, even if it is not a biography, because it contains material about living persons. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libellous. If such material is repeatedly inserted, or if you have other concerns, please report the issue to this noticeboard.If you are a subject of this article, or acting on behalf of one, and you need help, please see this help page. |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Removal of section
editI removed the below section of the draft because it is entirely sourced by his own research. He is a researcher, so doing research and writing papers is what he does. If any of his work is significant enough to be included in the article, it should be covered in independent reliable sources. I'm copying the text here so that it's a bit easier to access and possibly modify before any potential re-adding to the draft.
The other issue, which goes back to the referencing, is the unsourced statements such as "best known for" and "first to assess" - without independent sources these cannot be included. Primefac (talk) 02:25, 8 October 2017 (UTC)
Research
|
|---|
|
Zoghbi’s clinical research is best known for the development of non-invasive imaging modalities to evaluate cardiac disorders, particularly for valvular heart disease and cardiac function. In 1985 he became the first to assess the severity of aortic valve stenosis non-invasively by using the continuity equation and its simplified version to derive aortic valve area with Doppler echocardiography.[1] This is now the standard methodology used by echocardiography laboratories around the world to assess aortic stenosis.[2] Zoghbi’s laboratory applied the same principle to the evaluation of prosthetic valve function in the aortic and mitral positions, enhancing the identification of prosthetic valve stenosis and regurgitation.[3] He has also led studies validating real-time three-dimensional color Doppler for quantifying mitral regurgitation [4] and aortic regurgitation.[5] He was selected by the American Society of Echocardiography to chair the writing groups for the guidelines on the evaluation of native valve regurgitation (2003 and 2017) as well as the guidelines for assessment of prosthetic valve function (2009) and valve regurgitation after percutaneous valve repair or replacement (2017). In the area of ventricular function, he validated computational models of quantitation of regional cardiac function in animal models and in humans. He investigated pathophysiologic mechanisms of myocardial hibernation (viable but depressed heart function in chronic coronary artery disease that improves after coronary revascularization) and demonstrated that altered adrenergic receptor density and increased myocardial gene expression of tumor necrosis factor-alpha and nitric oxide synthase-2 in the myocardium contribute to the chronic downregulation of heart function in this condition.[6][7] His laboratory also developed methodology for detecting the viable myocardium with dobutamine echocardiography and described the biphasic response, a specific phenomenon with high predictive accuracy for improvement in cardiac function after revascularization in cases of myocardial hibernation.[8] His laboratory also used Doppler techniques to assess diastolic heart function in health and disease, and predict cardiac diastolic pressure non-invasively, which helps to differentiate symptoms of heart failure from other non-cardiac conditions.[9] References
|